<p><b>厄洛替尼</b>（英語：<span lang="en">Erlotinib</span>，商品名：Tarceva，<b>特羅凱</b>）是用於治療<span data-orig-title="非小细胞肺癌" data-lang-code="en" data-lang-name="英語" data-foreign-title="Non-small-cell lung carcinoma"><span>非小細胞肺癌</span></span>（NSCLC）、胰腺癌等幾種癌症的藥物，作為一種酪氨酸激酶抑制劑作用於表皮生長因子受體，由羅氏公司生產。
</p>
<h2><span id=".E8.97.A5.E7.89.A9.E5.90.88.E6.88.90"></span><span id="藥物合成">藥物合成</span></h2>
<ul><li>第一種合成路徑</li></ul><p>
</p>
<ul><li>第二種合成路徑</li></ul><p>
</p>
<h2><span id=".E5.8F.82.E8.80.83.E6.96.87.E7.8C.AE"></span><span id="参考文献">參考文獻</span></h2>

<h2><span id=".E5.A4.96.E9.83.A8.E9.93.BE.E6.8E.A5"></span><span id="外部链接">外部連結</span></h2>
<ul><li>Official Tarceva website （頁面存檔備份，存於網際網路檔案館）</li>
<li>Tarceva Discussion Group for Cancer Patients （頁面存檔備份，存於網際網路檔案館）</li>
<li><cite class="citation journal">Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. August 2004, <b>305</b> (5687): 1163–7. <span title="公共醫學識別碼">PMID 15284455</span>. <span title="數位物件識別號">doi:10.1126/science.1101637</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzh.wikipedia.org%3A%E5%8E%84%E6%B4%9B%E6%9B%BF%E5%B0%BC&amp;rft.atitle=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways&amp;rft.au=Sordella+R%2C+Bell+DW%2C+Haber+DA%2C+Settleman+J&amp;rft.date=2004-08&amp;rft.genre=article&amp;rft.issue=5687&amp;rft.jtitle=Science&amp;rft.pages=1163-7&amp;rft.volume=305&amp;rft_id=info%3Adoi%2F10.1126%2Fscience.1101637&amp;rft_id=info%3Apmid%2F15284455&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal"><span> </span></span>.</li>
<li>Genzyme "Genzyme Launches Exclusive Lung Cancer Test" Press Release September 27, 2005</li>
<li>"Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer （頁面存檔備份，存於網際網路檔案館）, <i>Journal of Clinical Oncology</i>, August 15, 2004.</li>
<li>October 2003 issue of <i>Lung Cancer Frontiers</i> on rash/effectiveness correlation</li>
<li><i>FAQ: I started an EGFR inhibitor two weeks ago but haven’t developed a rash. Does this mean it’s not working?</i>, Dr. Howard L. (Jack) West, M.D., <i>GRACE（頁面存檔備份，存於網際網路檔案館）</i>, February 21, 2011 (directed toward the layperson).</li>
<li>http://www.cancer.gov/clinicaltrials/results/lung-and-erlotinib0604l</li>
<li>https://web.archive.org/web/20081012081613/http://www.roche.com/med-cor-2007-10-22</li>
<li>https://web.archive.org/web/20110726060413/http://www.roche.com/med-cor-2009-05-30b</li>
<li>https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#27apr09</li>
<li>https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#20mar08</li></ul><!-- 
NewPP limit report
Parsed by mw1464
Cached time: 20230505230720
Cache expiry: 1814400
Reduced expiry: false
Complications: []
CPU time usage: 0.726 seconds
Real time usage: 0.914 seconds
Preprocessor visited node count: 8870/1000000
Post‐expand include size: 281258/2097152 bytes
Template argument size: 40009/2097152 bytes
Highest expansion depth: 28/100
Expensive parser function count: 45/500
Unstrip recursion depth: 0/20
Unstrip post‐expand size: 74/5000000 bytes
Lua time usage: 0.339/10.000 seconds
Lua memory usage: 24620456/52428800 bytes
Number of Wikibase entities loaded: 1/400
--><!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  749.388      1 -total
 42.50%  318.520      1 Template:Drugbox
 34.83%  261.041      1 Template:Infobox
 17.00%  127.374      1 Template:Lang-en
 16.18%  121.235      1 Template:Extracellular_chemotherapeutic_agents
 15.53%  116.397      1 Template:Navbox
 13.01%   97.470      2 Template:Navbox_subgroup
 12.95%   97.059     45 Template:Le
 12.37%   92.721      1 Template:Multiple_issues
  8.54%   63.993      4 Template:Ambox
-->
**厄洛替尼**（英語：Erlotinib，商品名：Tarceva，**特羅凱**）是用於治療非小細胞肺癌（NSCLC）、胰腺癌等幾種癌症的藥物，作為一種酪氨酸激酶抑制劑作用於表皮生長因子受體，由羅氏公司生產。

## 藥物合成

* 第一種合成路徑

* 第二種合成路徑

## 參考文獻

## 外部連結

* Official Tarceva website （頁面存檔備份，存於網際網路檔案館）
* Tarceva Discussion Group for Cancer Patients （頁面存檔備份，存於網際網路檔案館）
* Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. August 2004, **305** (5687): 1163–7. PMID 15284455. doi:10.1126/science.1101637. .
* Genzyme "Genzyme Launches Exclusive Lung Cancer Test" Press Release September 27, 2005
* "Determinants of Tumor Response and Survival With Erlotinib in Patients With Non-Small-Cell Lung Cancer （頁面存檔備份，存於網際網路檔案館）, _Journal of Clinical Oncology_, August 15, 2004.
* October 2003 issue of _Lung Cancer Frontiers_ on rash/effectiveness correlation
* _FAQ: I started an EGFR inhibitor two weeks ago but haven’t developed a rash. Does this mean it’s not working?_, Dr. Howard L. (Jack) West, M.D., _GRACE（頁面存檔備份，存於網際網路檔案館）_ , February 21, 2011 (directed toward the layperson).
* http://www.cancer.gov/clinicaltrials/results/lung-and-erlotinib0604l
* https://web.archive.org/web/20081012081613/http://www.roche.com/med-cor-2007-10-22
* https://web.archive.org/web/20110726060413/http://www.roche.com/med-cor-2009-05-30b
* https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#27apr09
* https://web.archive.org/web/20120918193637/http://www.cipla.com/whatsnew/news.htm#20mar08
183321-74-6